These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20007105)

  • 1. Chronic myeloid leukemia: where do we go now?
    Cortés JE
    Clin Lymphoma Myeloma; 2009; 9 Suppl 4():S374-5. PubMed ID: 20007105
    [No Abstract]   [Full Text] [Related]  

  • 2. Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia.
    Valent P
    Lancet Oncol; 2010 Nov; 11(11):1010-1. PubMed ID: 20965784
    [No Abstract]   [Full Text] [Related]  

  • 3. Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.
    Okabe S; Tauchi T; Ishii Y; Akahane D; Nunoda K; Honda S; Takaku T; Ohyashiki K
    Int J Hematol; 2007 Feb; 85(2):173-4. PubMed ID: 17321998
    [No Abstract]   [Full Text] [Related]  

  • 4. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
    Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
    [No Abstract]   [Full Text] [Related]  

  • 5. Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area.
    Park SJ; Choi IK; Seo HY; Sung HJ; Park KH; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Acta Haematol; 2007; 118(4):219-21. PubMed ID: 18057867
    [No Abstract]   [Full Text] [Related]  

  • 6. [TKI therapy for CML].
    Ohnishi K
    Rinsho Ketsueki; 2011 Jul; 52(7):452-9. PubMed ID: 21821976
    [No Abstract]   [Full Text] [Related]  

  • 7. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?
    Richter J; Söderlund S; Lübking A; Dreimane A; Lotfi K; Markevärn B; Själander A; Saussele S; Olsson-Strömberg U; Stenke L
    J Clin Oncol; 2014 Sep; 32(25):2821-3. PubMed ID: 25071107
    [No Abstract]   [Full Text] [Related]  

  • 8. [Management of chronic myeloid leukemia].
    Kubuki Y
    Rinsho Ketsueki; 2008 Oct; 49(10):1401-10. PubMed ID: 18833925
    [No Abstract]   [Full Text] [Related]  

  • 9. NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.
    Goulden S; Sutcliffe F; Stevens A
    Lancet Oncol; 2012 Feb; 13(2):127-8. PubMed ID: 22403810
    [No Abstract]   [Full Text] [Related]  

  • 10. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
    Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
    Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy.
    Breccia M; Cannella L; Nanni M; Stefanizzi C; Alimena G
    Acta Haematol; 2007; 118(3):162-4. PubMed ID: 17890849
    [No Abstract]   [Full Text] [Related]  

  • 12. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.
    Marin D; Goldman JM; Olavarria E; Apperley JF
    Blood; 2003 Oct; 102(7):2702-3; author reply 2703-4. PubMed ID: 14504074
    [No Abstract]   [Full Text] [Related]  

  • 13. What does a deep molecular response signify?
    Politi J; Shah NP
    J Clin Oncol; 2014 Feb; 32(5):471-4. PubMed ID: 24297955
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chronic myeloid leukemia 2008].
    Cervantes F
    Med Clin (Barc); 2008 Nov; 131(17):658-9. PubMed ID: 19087793
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
    Ito K; Tominaga K; Suzuki T; Jinnai I; Bessho M
    Int J Hematol; 2005 Apr; 81(3):242-5. PubMed ID: 15814335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drug targets genetic malfunction in chronic myeloid leukemia.
    Am J Health Syst Pharm; 2001 Jul; 58(14):1282. PubMed ID: 11471471
    [No Abstract]   [Full Text] [Related]  

  • 17. [Experimental advance of targeted medicines for chronic myeloid leukemia--review].
    Yang DG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):211-4. PubMed ID: 17490557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
    Pemmaraju N; Kantarjian H; Shan J; Jabbour E; Quintas-Cardama A; Verstovsek S; Ravandi F; Wierda W; O'Brien S; Cortes J
    Haematologica; 2012 Jul; 97(7):1029-35. PubMed ID: 22271898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.
    Otrock ZK; Mahfouz RA; Fahed Z; Farhat FS; Ziade A; Nasr F; Kassem N; Abboud MR
    Int J Hematol; 2012 Oct; 96(4):521-4. PubMed ID: 22961257
    [No Abstract]   [Full Text] [Related]  

  • 20. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.